SYNERGY has obtained the European Pharmacopoeia Adaptation Certificate
According to the Zhitong Finance APP, SYNERGY announced that the company recently received the revised Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor issued by the European Directorate for the Quality of Medicines (EDQM). The main reason for this change is the addition of a new production workshop, and the certification scope is: Ticagrelor active pharmaceutical ingredient. The revised certificate will take effect from September 12, 2025
According to the Zhitong Finance APP, SYNERGY (300636.SZ) announced that the company recently received the revised Certificate of Suitability (CEP) for Ticagrelor active pharmaceutical ingredient from the European Directorate for the Quality of Medicines (EDQM). The main reason for this revision is the addition of a new production workshop, and the certification scope is: Ticagrelor active pharmaceutical ingredient. The revised certificate will be effective from September 12, 2025
